
AAPG Stock Forecast & Price Target
AAPG Analyst Ratings
Bulls say
Ascentage Pharma Group is a promising investment opportunity due to its strong pipeline of drugs in development such as ELVN-001, TERN-701, and APG-3288, which have shown positive results in clinical trials and have potential for global sales. Additionally, their partnership with Takeda and developing drugs with unique mechanisms of action for treating multiple sclerosis and cancer adds to their strength in the market. However, as a clinical-stage biopharmaceutical company, there are associated risks, and investors should carefully consider the company's financials and pipeline progression.
Bears say
Ascentage Pharma Group is a clinical-stage biotechnology company that is focused on developing and selling small-scale therapies for cancers, hepatitis B virus, and age-related diseases. While the company has a diverse pipeline and promising drug candidates in research, its current financials and market positioning in China do not align with the potential risks and challenges associated with its drug development and commercialization process. Additionally, the company's partnership with Takeda for the option rights to olverembatinib outside of Greater China and Russia could limit its potential market reach and growth opportunities.
This aggregate rating is based on analysts' research of Ascentage Pharma Group International and is not a guaranteed prediction by Public.com or investment advice.
AAPG Analyst Forecast & Price Prediction
Start investing in AAPG
Order type
Buy in
Order amount
Est. shares
0 shares